This systematic review and dose-response meta-analysis evaluates the efficacy and tolerability of gefapixant, a new P2X3 antagonist, for the treatment of adults with refractory or unexplained chronic cough.
Source: JAMA Online First
| Curriculum Vitae | Résumé |
This systematic review and dose-response meta-analysis evaluates the efficacy and tolerability of gefapixant, a new P2X3 antagonist, for the treatment of adults with refractory or unexplained chronic cough.
Source: JAMA Online First